Investigational — Not FDA-Approved Authoritative Evidence Reference Research only (not FDA-approved)

Hexarelin (Examorelin)

Synthetic hexapeptide growth hormone-releasing peptide (examorelin); human studies in the 1990s on GH, prolactin and cortisol release and on desensitisation; not approved.

Language: English العربية (Arabic) →
Drug Class Growth hormone secretagogue; ghrelin receptor (GHSR) agonist.
FDA Regulatory Status Investigational — Not FDA-Approved
Clinical Stage Research only (not FDA-approved)
Evidence Verification Active Reference Standards
⚡

60-Second Scientific Briefing

Hexarelin (examorelin) is a synthetic six-amino-acid growth hormone-releasing peptide. It is not approved as a medicine. Human studies from the 1990s showed that it releases growth hormone strongly but also raises prolactin and cortisol, and that the growth hormone response fell by about 45% over 16 weeks of repeated injections in elderly volunteers before recovering after a break. Claims that it strengthens the heart or tendons are not established in people. It is prohibited in sport.

What is Hexarelin (Examorelin)?

Pharmacological Classification & Molecular Identity

Hexarelin (examorelin) is a synthetic hexapeptide growth hormone-releasing peptide. [1] J Clin Endocrinol Metab, 1996 ↗

Verified Chemical & Regulatory Registry Identifiers

Documented Aliases & Research Codes:
Examorelin

Mechanism of Action & Receptor Targets

Biological Pathway and Target Binding

Receptor Selectivity: Activates the ghrelin (growth hormone secretagogue) receptor, releasing growth hormone; in humans it also increases prolactin and cortisol. [1] J Clin Endocrinol Metab, 1996 ↗

Regulatory & FDA Approval Status

Legal and Regulatory Classifications
⚠️ STRICT REGULATORY NOTICE: UNAPPROVED INVESTIGATIONAL DRUG

Not approved by the US FDA or any other regulator; it is a research compound. Prohibited at all times by WADA (S2.2.4) as examorelin (hexarelin). [1] World Anti-Doping Agency, 2024 ↗ [2] Growth Horm IGF Res, 1998 ↗

Hexarelin (Examorelin) is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.

Human Evidence & Clinical Trials

Clinical Study Readouts and Evidence Syntheses

Dose-response study in healthy men (J Clin Endocrinol Metab 1996): intravenous hexarelin increased growth hormone, prolactin and cortisol in a dose-dependent way, and combined with GHRH caused massive growth hormone release. Desensitisation study (1998): in 12 healthy elderly people given repeated injections for 16 weeks, the growth hormone response fell significantly (area under the curve from 19.1 to 10.5) and recovered 4 weeks after stopping. No trial has shown benefit for the heart, tendons or muscle in people. [1] Growth Horm IGF Res, 1998 ↗ [2] J Clin Endocrinol Metab, 1996 ↗

Clinical Evidence

Dose-response study in healthy men (J Clin Endocrinol Metab 1996): intravenous hexarelin increased growth hormone, prolactin and cortisol in a dose-dependent way, and combined with GHRH caused massive growth hormone release. Desensitisation study (1998): in 12 healthy elderly people given repeated injections for 16 weeks, the growth hormone response fell significantly (area under the curve from 19.1 to 10.5) and recovered 4 weeks after stopping. No trial has shown benefit for the heart, tendons or muscle in people.

Safety Profile & Clinical Limitations

Documented Adverse Events and Known Uncertainties

Human studies showed rises in prolactin and cortisol alongside growth hormone. No long-term clinical safety dataset exists. [1] J Clin Endocrinol Metab, 1996 ↗

ℹ️ Active Research Safety Surveillance

Repeated use reduced the growth hormone response; heart and tendon claims are not established in humans; long-term safety and the quality of non-pharmaceutical material are unknown. [1] Growth Horm IGF Res, 1998 ↗

Dose Approval Status

Commercial Dosing Status and Policy Directives
🛑 NO APPROVED COMMERCIAL DOSING REGIMEN

No dose is approved or established. Amounts used in the published human studies are part of each study's design and are described in the linked papers; they are not a recommendation. [1] Growth Horm IGF Res, 1998 ↗

Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.

Storage & Handling Status: There is no approved product label, so no official storage instructions exist.

What is Known vs. What is Unknown

Evidence Comparison and Clinical Evidence Boundaries

✓ Confirmed Scientific Evidence

  • Hexarelin (examorelin) is a synthetic hexapeptide growth hormone-releasing peptide.
  • Targets & Selectivity: Activates the ghrelin (growth hormone secretagogue) receptor, releasing growth hormone; in humans it also increases prolactin and cortisol.
  • Dose-response study in healthy men (J Clin Endocrinol Metab 1996): intravenous hexarelin increased growth hormone, prolactin and cortisol in a dose-dependent way, and combined with GHRH caused massive growth hormone release. Desensitisation study (1998): in 12 healthy elderly people given repeated injections for 16 weeks, the growth hormone response fell significantly (area under the curve from 19.1 to 10.5) and recovered 4 weeks after stopping. No trial has shown benefit for the heart, tendons or muscle in people.
  • Safety considerations: Human studies showed rises in prolactin and cortisol alongside growth hormone. No long-term clinical safety dataset exists.

? Unknown / Under Ongoing Investigation

  • Repeated use reduced the growth hormone response; heart and tendon claims are not established in humans; long-term safety and the quality of non-pharmaceutical material are unknown.

Verified Questions & Answers

10 Verified scientific answers with permanent anchor keys
#1

What is Hexarelin (Examorelin) and how is it classified?

§
Direct Answer

Hexarelin (examorelin) is a synthetic six-amino-acid peptide that stimulates growth hormone release. It is a research compound, not an approved medicine.

Authoritative Citations:
#2

What is the mechanism of action and receptor profile of Hexarelin (Examorelin)?

§
Direct Answer

It activates the ghrelin (growth hormone secretagogue) receptor, releasing growth hormone, and in humans it also raises prolactin and cortisol.

Authoritative Citations:
#3

Is Hexarelin (Examorelin) approved by the US FDA or health authorities?

§
Direct Answer

No. Hexarelin is not approved by the FDA or any other regulator.

Authoritative Citations:
#4

What human clinical evidence and trials exist for Hexarelin (Examorelin)?

§
Direct Answer

Human studies from the 1990s showed dose-dependent rises in growth hormone, prolactin and cortisol, and a fall in the growth hormone response over 16 weeks of repeated use that recovered after a break. No trial has shown heart, tendon or muscle benefits in people.

Authoritative Citations:
#5

What adverse effects and safety risks are documented for Hexarelin (Examorelin)?

§
Direct Answer

Human studies showed rises in prolactin and cortisol together with growth hormone. There is no long-term clinical safety dataset.

Authoritative Citations:
#6

What are the critical unknown safety aspects and clinical limitations of Hexarelin (Examorelin)?

§
Direct Answer

Repeated use weakened the growth hormone response; heart and tendon claims are not established in humans; long-term safety and product quality are unknown.

Authoritative Citations:
#7

What is the approved dosing status for Hexarelin (Examorelin)?

§
Direct Answer

No dose is approved or established. Amounts used in the published human studies are part of each study's design and are described in the linked papers; they are not a recommendation.

Authoritative Citations:
#8

What are the storage and handling requirements for Hexarelin (Examorelin)?

§
Direct Answer

There is no approved product label, so no official storage instructions exist.

#9

Is Hexarelin (Examorelin) prohibited in competitive sports by WADA?

§
Direct Answer

Yes. Hexarelin (examorelin) is prohibited at all times under section S2.2.4 (growth hormone secretagogues and releasing factors) of the 2026 WADA Prohibited List.

Authoritative Citations:
#10

What is Egypt Peptides' official medical policy regarding Hexarelin (Examorelin)?

§
Direct Answer

Egypt Peptides publishes reviewed scientific reference monographs for documentation and research. The site does not give individual medical advice, preparation or injection instructions, combination protocols or off-label use instructions. Decisions about any medicine belong to the treating physician.

Authoritative Citations:

Authoritative Sources & Literature Registry

Regulatory dossiers, clinical trial registries, and published studies
Source [1] Tier 1 Regulatory / Academic

The Prohibited List ↗

Publisher / Registry: World Anti-Doping Agency Publication Date: 2024-01-01
Verified Locator: https://www.wada-ama.org/en/prohibited-list
Source [2] Tier 1 Regulatory / Academic

Does desensitization to hexarelin occur? ↗

Publisher / Registry: Growth Horm IGF Res Publication Date: 1998-01-01 PubMed PMID: 10990150
Verified Locator: https://pubmed.ncbi.nlm.nih.gov/10990150/
Source [3] Tier 1 Regulatory / Academic

Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study ↗

Publisher / Registry: J Clin Endocrinol Metab Publication Date: 1996-12-01 PubMed PMID: 8954038
Verified Locator: https://pubmed.ncbi.nlm.nih.gov/8954038/

Related Knowledge Entities

5-Amino-1MQ Adipotide (FTPP) Afamelanotide AHK-Cu AICAR (Acadesine) AOD-9604